Form 4: Amylyx Pharmaceuticals Chief Legal Officer Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Gina Mazzariello, Chief Legal Officer of Amylyx Pharmaceuticals, acquired stock options and restricted stock units (RSUs) as part of her compensation.
Summary
- On April 16, 2024, Gina Mazzariello, the Chief Legal Officer of Amylyx Pharmaceuticals, received 80,560 restricted stock units (RSUs) and stock options for 110,000 shares.
- The RSUs vest in three tranches: 33% on September 30, 2024, 33% on March 31, 2025, and 34% on September 30, 2025, contingent upon continued service.
- The stock options, priced at $2.01, vest 25% on April 16, 2025, with the remaining shares vesting monthly over the subsequent 36 months, also subject to continued service.
- Following these transactions, Mazzariello directly owns 161,932 shares of common stock and holds options for 110,000 shares.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to slightly positive as it suggests confidence in the company's future.
Positives
- The granting of RSUs and stock options aligns the Chief Legal Officer's interests with the long-term success of Amylyx Pharmaceuticals.
- The vesting schedules for both RSUs and stock options incentivize continued service and commitment from the executive.
Industry Context
Stock options and RSU grants are common compensation practices for executives in publicly traded companies, particularly in the pharmaceutical industry, to align their interests with shareholder value and incentivize long-term performance.
Comparison to Industry Standards
- Equity compensation packages for Chief Legal Officers in similar-sized pharmaceutical companies typically include a mix of stock options and restricted stock units.
- The vesting schedules are fairly standard, with vesting periods ranging from three to four years, contingent upon continued employment.
- The specific amounts and terms of the grants would be benchmarked against peer companies to ensure competitiveness and alignment with performance goals.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with long-term value creation.
- Employees may see this as a positive indicator of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 04/16/2024 | Date of transaction: Grant of RSUs and stock options to Gina Mazzariello. |
| 09/30/2024 | First vesting date for 33% of the RSUs. |
| 03/31/2025 | Second vesting date for 33% of the RSUs. |
| 04/16/2025 | First vesting date for 25% of the stock options. |
| 09/30/2025 | Final vesting date for 34% of the RSUs. |
| 04/15/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.